pantoprazole and Helicobacter Infections
pantoprazole has been researched along with Helicobacter Infections in 199 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
"To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease." | 9.12 | Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007) |
"To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
"To study the efficacy of three pantoprazole-based triple therapy regimens for the eradication of Helicobacter pylori infection and gastric ulcer healing." | 9.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
" pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 9.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
" pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 9.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
" pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 9.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
" The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 9.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
"Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
"3%) and there were no serious adverse events." | 6.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
"Clarithromycin resistance was detected in 33/190 patients (17." | 5.51 | Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019) |
"Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 5.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
"The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy." | 5.14 | Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009) |
"In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
"To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease." | 5.12 | Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007) |
" pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b." | 5.11 | Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004) |
" pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)." | 5.10 | [Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002) |
"To study the efficacy of three pantoprazole-based triple therapy regimens for the eradication of Helicobacter pylori infection and gastric ulcer healing." | 5.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
"To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
"To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
"Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days." | 5.09 | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001) |
"For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b." | 5.09 | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000) |
" pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 5.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
" pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 5.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
"In this open, randomized, monocenter, parallel group comparison, 107 patients with duodenal ulcer or functional dyspepsia were assigned to receive one of the following treatment regimens: a 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid, which was either preceded or followed by a 7-day therapy with pantoprazole, 40 mg (P-PCM or PCM-P)." | 5.09 | Pantoprazole suppresses Helicobacter pylori without affecting cure. ( Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999) |
" pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 5.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
"pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
" The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 5.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
"Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
"Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4." | 3.85 | Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ( Altinbas, A; Babaoglu, MO; Bozkurt, A; Goktas, MT; Kalkisim, S; Karaca, RO; Kilincalp, S; Yasar, U; Yuksel, I, 2017) |
"Following healing of endoscopically confirmed peptic ulcer or reflux oesophagitis during 4-12 weeks' treatment with pantoprazole (40-80 mg/day), adult patients received open-label maintenance treatment with pantoprazole (40-160 mg/day) for up to 15 years in a single centre combined study (10-year initial study; 5-year extension study)." | 3.78 | Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. ( Athmann, C; Brunner, G; Schneider, A, 2012) |
" pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole." | 3.76 | Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. ( Bielicki, D; Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Marlicz, W; Siuda, A, 2010) |
"The development of eosinophilic gastritis immediately after Helicobacter pylori eradication has not previously been described: A 62-year-old woman developed eosinophilic gastritis immediately after a triple therapy for Helicobacter pylori eradication, consisting of pantoprazole, amoxicillin and clarithromycin." | 3.74 | [Eosinophilic gastritis after helicobacter pylori eradication]. ( Aigner, T; Fritzsch, J; Krügel, V; Pluta, L; Schütz, A, 2008) |
"This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years." | 3.73 | Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005) |
"The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated." | 3.68 | Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. ( Dorrian, CA; Fullarton, GM; Harwood, J; Macdonald, AM; McColl, KE; Nujumi, AM, 1992) |
"Clarithromycin resistance was an independent risk factor predicting eradication failure in standard triple group (P < 0." | 2.80 | A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. ( Chen, A; Chen, WC; Cheng, JS; Chuah, SK; Hsu, PI; Kao, SS; Lai, KH; Peng, NJ; Tsay, FW; Wang, HM; Wu, DC; Yu, HC, 2015) |
"Halitosis was significantly more prevalent in the group of patients with persistent H." | 2.80 | Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating. ( Bojic, B; Milasin, J; Popovic, B; Zaric, S, 2015) |
"SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin." | 2.79 | [Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy]. ( Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014) |
" Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration." | 2.77 | A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. ( Bari, Z; Fakheri, H; Sardarian, H, 2012) |
"The optimal dosage of intravenous proton pump inhibitors (PPIs) for the prevention of peptic ulcer rebleeding remains unclear." | 2.77 | Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. ( Chen, CC; Fang, YJ; Han, ML; Hsu, SJ; Hu, FC; Lee, JY; Lin, JT; Lin, TL; Liou, JM; Tseng, PH; Wang, HP; Wu, MS, 2012) |
"Erdosteine is an efficient adjuvant therapy that could be used in conjunction with first-line triple therapy in the treatment of H." | 2.75 | Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. ( Abut, E; Bölükbaş, C; Bölükbaş, FF; Dalay, AR; Güveli, H; Kurdaş, OO; Yaşar, B, 2010) |
"Fifty-six consecutive patients with type 2 diabetes mellitus and 58 age- and sex-matched control patients were included in the study." | 2.74 | Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. ( Arslan, H; Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U, 2009) |
"Pantoprazole (40 mg/day) was given to 27 patients for 28 days and ranitidine (300 mg." | 2.74 | Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. ( Dağalp, K; Ilgan, S; Ozgüven, M; Oztürk, E; Yeşilova, Z, 2009) |
"Treatment with omeprazole or pantoprazole prior to urea breath test (UBT) was associated with low false negative results, while lansoprazole and esomeprazole caused clinically unacceptable high false negative rates (pantoprazole 2." | 2.71 | Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. ( Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H, 2004) |
" Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0." | 2.71 | Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003) |
"3%) and there were no serious adverse events." | 2.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
" Treatment was safe; only four patients had adverse events definitely related to pantoprazole." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
" No studies have yet compared the effects of different dosages of clarithromycin in combination with a proton pump inhibitor and amoxicillin in elderly patients." | 2.70 | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ( Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001) |
"Metronidazole resistance was found in 44% of pre-treatment cultures of H." | 2.69 | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000) |
" pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently." | 2.69 | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. ( Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000) |
"Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
"We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics." | 2.42 | Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. ( Beckerling, A; Gatz, G; Ulmer, HJ, 2003) |
" Pantoprazole is well absorbed when administered as an enteric-coated, delayed-release tablet, with an oral bioavailability of approximately 77%." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
" Adverse drug effects were found in 36 patients from the twice a day group and 50 patients from the four times a day group (P = ." | 1.56 | Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. ( Kim, JH; Kim, JY; Lee, SY; Park, HS; Sung, IK, 2020) |
"Clarithromycin resistance was detected in 33/190 patients (17." | 1.51 | Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019) |
"Curcumin was filtered using Lipinski's rule of five and the druglikeness property for evaluation of pharmacological properties." | 1.42 | In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. ( Roy, BK; Shukla, HS; Srivastava, AK; Tewari, M, 2015) |
"The mucosal folds in Menetrier's disease are often most prominent in the body and fundus." | 1.37 | [A case of Menetrier's disease showing mucus bridge observed during endoscopy]. ( Hwang, JM; Kim, GH; Kim, WJ; Lee, HS; Lee, HW; Park, DY; Ryu, DY; Song, GA, 2011) |
"Burkitt's lymphoma is a highly aggressive non-Hodgkin lymphoma, often presenting in extra-nodal sites." | 1.35 | Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. ( Baia, M; Baumgaertner, I; Charachon, A; Copie-Bergman, C; Delchier, JC; Haioun, C; Levy, M; Sobhani, I, 2009) |
"Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e." | 1.33 | Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005) |
"Metronidazole is a good substitute for clarithromycin as the second-line option for children." | 1.32 | Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004) |
"Metronidazole resistance was reported in a high percentage of strains isolated from patients." | 1.31 | Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. ( Cheah, P; Chin, S; Goh, K; Parasakthi, N; Ranjeev, C; Rosmawati, M; Tan, Y, 2000) |
"Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 1.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
Research
Studies (199)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 29 (14.57) | 18.2507 |
2000's | 103 (51.76) | 29.6817 |
2010's | 64 (32.16) | 24.3611 |
2020's | 3 (1.51) | 2.80 |
Authors
Authors | Studies |
---|---|
Jain, KS | 1 |
Shah, AK | 1 |
Bariwal, J | 1 |
Shelke, SM | 1 |
Kale, AP | 1 |
Jagtap, JR | 1 |
Bhosale, AV | 1 |
Jha, SK | 1 |
Mishra, MK | 1 |
Saharawat, K | 1 |
Jha, P | 1 |
Purkayastha, S | 1 |
Ranjan, R | 1 |
Kim, JY | 2 |
Lee, SY | 1 |
Kim, JH | 2 |
Sung, IK | 1 |
Park, HS | 1 |
Şenocak Taşçı, E | 1 |
Akbaş, T | 1 |
Jonaitis, P | 1 |
Jonaitis, L | 1 |
Kupcinskas, J | 1 |
Souto Filho, JTD | 1 |
Lemos, LVB | 1 |
Vieira Junior, MC | 1 |
Barboza, KP | 1 |
Castelar, BM | 1 |
Ribeiro, AEL | 1 |
da Silva, FC | 1 |
Boal Carvalho, P | 1 |
Magalhães, J | 1 |
Dias de Castro, F | 1 |
Rosa, B | 1 |
Cotter, J | 1 |
Tsay, FW | 6 |
Wu, DC | 5 |
Yu, HC | 5 |
Kao, SS | 4 |
Lin, KH | 1 |
Cheng, JS | 3 |
Wang, HM | 5 |
Chen, WC | 5 |
Sun, WC | 1 |
Tsai, KW | 2 |
Hsu, PI | 7 |
Park, JS | 2 |
Park, JE | 1 |
Oh, BS | 1 |
Yoon, BW | 1 |
Kim, HK | 1 |
Lee, JW | 1 |
Kim, NH | 1 |
Cho, WS | 1 |
Woo, YS | 1 |
Jahng, J | 1 |
Kim, YS | 2 |
Pan, CY | 1 |
Kao, JY | 1 |
Peng, NJ | 4 |
Tsai, TJ | 1 |
Chen, CL | 1 |
Chang, YW | 1 |
Ko, WJ | 1 |
Oh, CH | 1 |
Park, YM | 1 |
Oh, SJ | 2 |
Moon, JR | 1 |
Cho, JH | 1 |
Kim, JW | 2 |
Jang, JY | 1 |
Ennkaa, A | 1 |
Shaath, N | 1 |
Salam, A | 1 |
Mohammad, RM | 1 |
Joosten, M | 1 |
Flahou, B | 1 |
Meyns, T | 1 |
Smet, A | 1 |
Arts, J | 1 |
De Cooman, L | 1 |
Pasmans, F | 1 |
Ducatelle, R | 1 |
Haesebrouck, F | 1 |
Cecchini, MP | 1 |
Pellegrini, C | 1 |
Bassetto, MA | 1 |
Osculati, F | 1 |
Sbarbati, A | 1 |
Marcolini, L | 1 |
Pegoraro, M | 1 |
Fontana, R | 1 |
De Franceschi, L | 1 |
Nasa, M | 1 |
Choksey, A | 1 |
Phadke, A | 1 |
Sawant, P | 1 |
Trifan, A | 1 |
Girleanu, I | 1 |
Cojocariu, C | 1 |
Sfarti, C | 1 |
Singeap, AM | 1 |
Dorobat, C | 1 |
Grigore, L | 1 |
Stanciu, C | 1 |
Tseng, HH | 4 |
Lai, KH | 5 |
Chen, A | 3 |
Berry, AC | 1 |
Nakshabendi, R | 1 |
Baltz, AC | 1 |
Metanat, HA | 1 |
Valizadeh, SM | 1 |
Fakheri, H | 4 |
Maleki, I | 2 |
Taghvaei, T | 3 |
Hosseini, V | 3 |
Bari, Z | 3 |
Koval', VIu | 1 |
Kotsiubniak, LA | 1 |
Moskal', OM | 1 |
Almeida, N | 1 |
Donato, MM | 1 |
Romãozinho, JM | 1 |
Luxo, C | 1 |
Cardoso, O | 1 |
Cipriano, MA | 1 |
Marinho, C | 1 |
Fernandes, A | 1 |
Calhau, C | 1 |
Sofia, C | 1 |
Hauser, G | 1 |
Salkic, N | 1 |
Vukelic, K | 1 |
JajacKnez, A | 1 |
Stimac, D | 3 |
Srivastava, AK | 1 |
Tewari, M | 1 |
Shukla, HS | 1 |
Roy, BK | 1 |
Zaric, S | 2 |
Bojic, B | 2 |
Popovic, B | 2 |
Milasin, J | 2 |
Sapmaz, F | 1 |
Kalkan, IH | 1 |
Suslu, I | 1 |
Demirci, H | 1 |
Atasoy, P | 1 |
Guliter, S | 1 |
Gungor, G | 1 |
Baglıcakoglu, M | 1 |
Kayacetin, E | 1 |
Biyik, M | 1 |
Ucar, R | 1 |
Goktepe, H | 1 |
Ataseven, H | 3 |
Demir, A | 1 |
Curth, HM | 1 |
Dinter, J | 1 |
Nigemeier, K | 1 |
Kütting, F | 1 |
Hunzelmann, N | 1 |
Steffen, HM | 1 |
Apostolopoulos, P | 1 |
Koumoutsos, I | 1 |
Ekmektzoglou, K | 1 |
Dogantzis, P | 1 |
Vlachou, E | 1 |
Kalantzis, C | 1 |
Tsibouris, P | 1 |
Alexandrakis, G | 1 |
Chuah, SK | 1 |
Chan, CC | 1 |
Chien, NH | 1 |
Lee, CL | 1 |
Yang, YC | 1 |
Hung, CS | 1 |
Tu, TC | 1 |
Wu, CH | 1 |
Ciccaglione, AF | 2 |
Tavani, R | 1 |
Grossi, L | 2 |
Cellini, L | 2 |
Manzoli, L | 1 |
Marzio, L | 2 |
Ormeci, A | 1 |
Emrence, Z | 1 |
Baran, B | 1 |
Gokturk, S | 2 |
Soyer, OM | 1 |
Evirgen, S | 1 |
Akyuz, F | 1 |
Karaca, C | 1 |
Besisik, F | 1 |
Kaymakoglu, S | 1 |
Ustek, D | 1 |
Demir, K | 1 |
Dore, MP | 2 |
Soro, S | 1 |
Rocchi, C | 1 |
Loria, MF | 1 |
Bibbò, S | 1 |
Pes, GM | 1 |
Park, SM | 1 |
Kim, JS | 3 |
Kim, BW | 1 |
Ji, JS | 1 |
Choi, H | 1 |
Karaca, RO | 1 |
Kalkisim, S | 1 |
Altinbas, A | 1 |
Kilincalp, S | 1 |
Yuksel, I | 1 |
Goktas, MT | 1 |
Yasar, U | 1 |
Bozkurt, A | 1 |
Babaoglu, MO | 1 |
Marušić, M | 2 |
Dominković, L | 1 |
Majstorović Barać, K | 1 |
Gulić, S | 1 |
Bago, J | 1 |
Pezerović, D | 2 |
Çekin, AH | 1 |
Şahintürk, Y | 1 |
Akbay Harmandar, F | 1 |
Uyar, S | 1 |
Yolcular, BO | 1 |
Çekin, Y | 1 |
Jung, HS | 1 |
Shim, KN | 1 |
Baik, SJ | 1 |
Na, YJ | 1 |
Kang, MJ | 1 |
Jung, JM | 1 |
Ha, CY | 1 |
Jung, SA | 1 |
Yoo, K | 1 |
Kang, JM | 1 |
Kim, N | 3 |
Lee, DH | 3 |
Park, YS | 2 |
Chang, IJ | 1 |
Song, IS | 3 |
Jung, HC | 3 |
Villoria, A | 1 |
Garcia, P | 1 |
Calvet, X | 3 |
Gisbert, JP | 5 |
Vergara, M | 2 |
Oh, JH | 1 |
Dong, MS | 1 |
Choi, MG | 1 |
Yoo, HW | 1 |
Lee, SB | 1 |
Park, YI | 1 |
Chung, IS | 1 |
Fritzsch, J | 1 |
Krügel, V | 1 |
Aigner, T | 1 |
Pluta, L | 1 |
Schütz, A | 1 |
Hong, EJ | 1 |
Park, DI | 2 |
Song, MJ | 1 |
Choi, WH | 1 |
Hong, CH | 1 |
Park, JH | 1 |
Kim, HJ | 2 |
Cho, YK | 2 |
Shon, CI | 1 |
Jeon, WK | 2 |
Kim, BI | 2 |
Labenz, J | 3 |
Armstrong, D | 1 |
Zetterstrand, S | 1 |
Eklund, S | 1 |
Leodolter, A | 2 |
Pellicano, R | 1 |
Oztürk, E | 1 |
Yeşilova, Z | 3 |
Ilgan, S | 2 |
Ozgüven, M | 1 |
Dağalp, K | 2 |
Jankovic, Lj | 1 |
Dapcevic, B | 1 |
Cakic, S | 1 |
Hunfeld, NG | 1 |
Touw, DJ | 1 |
Mathot, RA | 1 |
Mulder, PG | 1 |
VAN Schaik, RH | 1 |
Kuipers, EJ | 1 |
Kooiman, JC | 1 |
Geus, WP | 1 |
Ng, FH | 1 |
Wong, SY | 1 |
Lam, KF | 1 |
Chu, WM | 1 |
Chan, P | 1 |
Ling, YH | 1 |
Kng, C | 1 |
Yuen, WC | 1 |
Lau, YK | 1 |
Kwan, A | 1 |
Wong, BC | 1 |
Demir, M | 5 |
Gokturk, HS | 2 |
Ozturk, NA | 3 |
Arslan, H | 1 |
Serin, E | 3 |
Yilmaz, U | 3 |
Dabos, KJ | 1 |
Sfika, E | 1 |
Vlatta, LJ | 1 |
Giannikopoulos, G | 1 |
Baumgaertner, I | 1 |
Copie-Bergman, C | 1 |
Levy, M | 1 |
Haioun, C | 1 |
Charachon, A | 1 |
Baia, M | 1 |
Sobhani, I | 1 |
Delchier, JC | 1 |
Gen, R | 2 |
Abut, E | 1 |
Yaşar, B | 1 |
Güveli, H | 1 |
Bölükbaş, C | 1 |
Bölükbaş, FF | 1 |
Dalay, AR | 1 |
Kurdaş, OO | 2 |
Gawrońska-Szklarz, B | 2 |
Siuda, A | 1 |
Kurzawski, M | 1 |
Bielicki, D | 1 |
Marlicz, W | 1 |
Droździk, M | 2 |
Cetinkaya, ZA | 1 |
Sezikli, M | 1 |
Güzelbulut, F | 1 |
Coşgun, S | 1 |
Düzgün, S | 1 |
Lassnig, RM | 1 |
Chang, AH | 1 |
Haggerty, TD | 1 |
de Martel, C | 1 |
Leung, CW | 1 |
Parsonnet, J | 1 |
Qua, CS | 1 |
Manikam, J | 1 |
Goh, KL | 2 |
Yakut, M | 1 |
Çinar, K | 1 |
Seven, G | 1 |
Bahar, K | 1 |
Özden, A | 1 |
Hwang, JM | 1 |
Kim, GH | 2 |
Kim, WJ | 1 |
Lee, HS | 1 |
Lee, HW | 1 |
Ryu, DY | 2 |
Song, GA | 2 |
Park, DY | 1 |
Cheong, JH | 1 |
Lee, BE | 1 |
Choi, MK | 1 |
Moon, JY | 1 |
Kim, DU | 1 |
Gu, LY | 1 |
Lin, WW | 1 |
Lu, H | 1 |
Chen, XY | 1 |
Ge, ZZ | 1 |
Li, XB | 1 |
Chung, JW | 1 |
Lee, JH | 2 |
Jung, HY | 1 |
Yun, SC | 1 |
Oh, TH | 1 |
Choi, KD | 1 |
Song, HJ | 1 |
Lee, GH | 1 |
Farina, V | 1 |
Cuccu, M | 1 |
Mameli, L | 1 |
Massarelli, G | 1 |
Graham, DY | 2 |
Wang, KM | 1 |
Lee, CC | 1 |
Chang, SN | 1 |
Park, HK | 1 |
Jo, HJ | 1 |
Shin, CM | 1 |
Lee, SH | 1 |
Hwang, JH | 1 |
Jeong, SH | 1 |
Nam, RH | 1 |
Kim, JM | 2 |
Kim, SJ | 1 |
Yoon, JH | 1 |
Suk, KT | 1 |
Kim, JB | 1 |
Kim, DJ | 1 |
Kim, DY | 1 |
Min, HJ | 1 |
Park, SH | 1 |
Shin, WG | 1 |
Kim, KH | 1 |
Kim, HY | 1 |
Baik, GH | 1 |
Holtmann, G | 2 |
van Rensburg, C | 1 |
Schwan, T | 2 |
Sander, P | 2 |
Siffert, W | 1 |
Kım, KJ | 1 |
Park, MI | 1 |
Park, SJ | 1 |
Cho, SW | 1 |
Moon, W | 1 |
Kim, GM | 1 |
Kim, WM | 1 |
Shcherbakov, PL | 1 |
Ianova, OB | 1 |
Belousova, NL | 1 |
Masharova, AA | 1 |
Shcherbakova, MIu | 1 |
Goncharenko, LS | 1 |
Firsova, LD | 1 |
Kim, VA | 1 |
Govorun, VM | 1 |
Kashnikov, VS | 1 |
Chen, CC | 1 |
Lee, JY | 1 |
Fang, YJ | 1 |
Hsu, SJ | 1 |
Han, ML | 1 |
Tseng, PH | 1 |
Liou, JM | 1 |
Hu, FC | 1 |
Lin, TL | 1 |
Wu, MS | 1 |
Wang, HP | 1 |
Lin, JT | 1 |
Brunner, G | 1 |
Athmann, C | 1 |
Schneider, A | 2 |
Sardarian, H | 2 |
Gashi, Z | 1 |
Joksimovic, N | 1 |
Dragusha, G | 1 |
Bakalli, A | 1 |
Mokhtare, M | 1 |
Boixeda, D | 3 |
Bermejo, F | 2 |
Martín-De-Argila, C | 1 |
López-Sanromán, A | 1 |
Defarges, V | 1 |
Hernández-Ranz, F | 1 |
Milicua, JM | 1 |
García-Plaza, A | 1 |
Queiroz, DM | 1 |
Dani, R | 1 |
Silva, LD | 1 |
Santos, A | 1 |
Moreira, LS | 1 |
Rocha, GA | 1 |
Corrêa, PR | 1 |
Reis, LF | 1 |
Nogueira, AM | 1 |
Alvares Cabral, MM | 1 |
Esteves, AM | 1 |
Tanure, J | 1 |
Cui, M | 1 |
Hu, F | 1 |
Jiang, H | 1 |
Zheng, X | 1 |
Cheer, SM | 1 |
Prakash, A | 1 |
Faulds, D | 1 |
Lamb, HM | 1 |
Dulbecco, P | 1 |
Gambaro, C | 1 |
Bilardi, C | 1 |
Zentilin, P | 1 |
Mele, MR | 1 |
Mansi, C | 1 |
Biagini, R | 1 |
Tessieri, L | 1 |
Iiritano, E | 1 |
Usai, P | 1 |
Vigneri, S | 1 |
Savarino, V | 2 |
Ulmer, HJ | 1 |
Beckerling, A | 1 |
Gatz, G | 3 |
Malfertheiner, P | 2 |
Kirchner, T | 2 |
Kist, M | 2 |
Peitz, U | 2 |
Strobel, S | 2 |
Bohuschke, M | 1 |
Martín De Argila, C | 2 |
López Sanromán, A | 1 |
Hernández Ranz, F | 1 |
García Plaza, A | 2 |
de Boer, SY | 1 |
v d Meeberg, PC | 1 |
Siem, H | 1 |
de Boer, WA | 1 |
Perri, F | 6 |
Festa, V | 4 |
Merla, A | 1 |
Barberani, F | 1 |
Pilotto, A | 6 |
Andriulli, A | 5 |
Bochenek, WJ | 2 |
Peters, S | 1 |
Fraga, PD | 2 |
Wang, W | 1 |
Mack, ME | 2 |
Osato, MS | 1 |
El-Zimaity, HM | 1 |
Davis, KD | 1 |
Khorrami, S | 1 |
Pajares, JM | 2 |
Singh, G | 1 |
Levine, A | 1 |
Shevah, O | 1 |
Shabat-Sehayek, V | 1 |
Aeed, H | 1 |
Boaz, M | 1 |
Moss, SF | 1 |
Niv, Y | 1 |
Avni, Y | 1 |
Shirin, H | 1 |
Wu, CJ | 2 |
Lo, GH | 2 |
Lo, CC | 2 |
Lin, CK | 2 |
Shie, CB | 1 |
Jou, HS | 1 |
Tsai, PM | 1 |
Chen, JL | 2 |
Yukselen, V | 1 |
Yasa, MH | 1 |
Karaoglu, AO | 1 |
Ghazzawi, IM | 1 |
Obeidat, WA | 1 |
Zuriekat, FA | 1 |
Sivri, B | 1 |
Simsek, I | 1 |
Hulagu, S | 1 |
Kadayifci, A | 4 |
Tozun, N | 1 |
Akarsu, M | 1 |
Uraz, S | 1 |
Savas, MC | 2 |
Koruk, M | 1 |
Bozbas, A | 1 |
Franceschi, M | 4 |
Longoa, MG | 1 |
Scarcelli, C | 1 |
Orsitto, G | 1 |
Perri, FC | 1 |
D'Ambrosio, LP | 1 |
Leandro, G | 5 |
Kato, S | 1 |
Konno, M | 1 |
Maisawa, S | 1 |
Tajiri, H | 1 |
Yoshimura, N | 1 |
Shimizu, T | 1 |
Toyoda, S | 1 |
Nakayama, Y | 1 |
Iinuma, K | 1 |
Buzás, GM | 2 |
Metz, DC | 1 |
Bardhan, KD | 5 |
Bishop, AE | 2 |
Polak, JM | 2 |
Romanska, HM | 1 |
Rowland, A | 2 |
Thompson, M | 3 |
Morris, P | 3 |
Schaefer-Preuss, S | 1 |
Luehmann, R | 1 |
McCaldin, B | 3 |
Calleja, JL | 1 |
Suarez, M | 1 |
De Tejada, AH | 1 |
Navarro, A | 1 |
Babic, Z | 1 |
Nesanovic, M | 1 |
Lucijanic-Mlinac, M | 1 |
Stajcar, V | 1 |
Wrześniewska, J | 1 |
Starzyńska, T | 1 |
Pawlik, A | 1 |
Safranow, K | 1 |
Ferenc, K | 1 |
Uygun, A | 2 |
Ateş, Y | 1 |
Karslioğlu, Y | 1 |
Ciğerim, M | 1 |
Bağci, S | 1 |
Yamaoka, Y | 1 |
Vakil, N | 1 |
Okazaki, K | 1 |
Mori, S | 1 |
Tahashi, K | 1 |
Borody, TJ | 1 |
Pang, G | 1 |
Wettstein, AR | 1 |
Clancy, R | 1 |
Herdman, K | 1 |
Surace, R | 1 |
Llorente, R | 1 |
Ng, C | 1 |
Aladağ, M | 1 |
Kantarçeken, B | 1 |
Karincaoğlu, M | 1 |
Sertkaya, A | 1 |
Cikim, K | 1 |
Harputluoğlu, MM | 1 |
Demirel, U | 1 |
Alan, H | 1 |
Ateş, F | 1 |
Yildirim, B | 1 |
Hilmioğlu, F | 1 |
Manes, G | 1 |
Ferrara, EC | 1 |
Porro, GB | 1 |
Sezgin, O | 3 |
Altintaş, E | 3 |
Uçbilek, E | 3 |
Tataroğlu, C | 1 |
Cheon, JH | 1 |
Kim, SG | 1 |
Dietrich, JW | 1 |
Boehm, BO | 1 |
Ziemniak, W | 1 |
Yilmaz, S | 1 |
Bayan, K | 1 |
Dursun, M | 1 |
Canoruç, F | 1 |
Kilinç, N | 1 |
Tüzün, Y | 1 |
Daniş, R | 1 |
Ertem, M | 1 |
González Carro, P | 1 |
Pérez Roldán, F | 1 |
De Pedro Esteban, A | 1 |
Legaz Huidobro, ML | 1 |
Soto Fernández, S | 1 |
Roncero Garcia Escribano, O | 1 |
Esteban López-Jamar, JM | 1 |
Pedraza Martin, C | 1 |
Ruíz Carrillo, F | 1 |
Hartmann, D | 1 |
Eickhoff, A | 1 |
Damian, U | 1 |
Riemann, JF | 1 |
Schilling, D | 1 |
Benamouzig, R | 1 |
Di Mario, F | 3 |
Cavallaro, LG | 1 |
Nouvenne, A | 1 |
Stefani, N | 1 |
Cavestro, GM | 1 |
Iori, V | 1 |
Maino, M | 1 |
Comparato, G | 1 |
Fanigliulo, L | 1 |
Morana, E | 1 |
Martelli, L | 1 |
Martelli, M | 1 |
Franzè, A | 1 |
Mahachai, V | 1 |
Thong-Ngam, D | 1 |
Noophun, P | 1 |
Tumwasorn, S | 1 |
Kullavanijaya, P | 1 |
Tombak, A | 1 |
Tellioğlu, B | 1 |
Nayir, E | 1 |
Choi, HS | 1 |
Hwang, SJ | 1 |
Sohn, CI | 1 |
Széles, I | 1 |
Safali, M | 1 |
Karaeren, N | 1 |
Abdullahi, M | 1 |
Annibale, B | 1 |
Capoccia, D | 1 |
Tari, R | 1 |
Lahner, E | 1 |
Osborn, J | 1 |
Leonetti, F | 1 |
Severi, C | 1 |
Tillenburg, B | 2 |
Becker, T | 1 |
Börsch, G | 1 |
Stolte, M | 4 |
Adamek, RJ | 6 |
Szymanski, C | 4 |
Pfaffenbach, B | 4 |
Opferkuch, W | 1 |
Ricken, D | 1 |
Wegener, M | 1 |
Weismüller, J | 1 |
Lütke, A | 1 |
Seelis, RE | 1 |
Dohmen, W | 1 |
Glaser, J | 1 |
Hein, J | 1 |
Daikeler, R | 1 |
Weithofer, G | 1 |
Vieth, M | 1 |
Schmidt, M | 1 |
Treiber, G | 1 |
Lambert, JR | 1 |
Louw, JA | 1 |
van Rensburg, CJ | 1 |
Hanslo, D | 1 |
Grundlings, HD | 1 |
Girdwood, AH | 1 |
Marks, IN | 1 |
Morton, D | 1 |
Slater, DN | 1 |
Perry, MJ | 2 |
Cherian, P | 2 |
Jones, RB | 1 |
Brookes, A | 1 |
Ellenrieder, V | 2 |
Fensterer, H | 1 |
Waurick, M | 1 |
Adler, G | 2 |
Glasbrenner, B | 2 |
Améndola, R | 1 |
Roldán, CD | 1 |
Morgade, L | 1 |
Solagna, A | 1 |
Lineado, A | 1 |
Musi, AO | 1 |
Valero, J | 1 |
Zerbo, O | 1 |
Kogan, Z | 1 |
Ferro, FE | 1 |
Schenone, L | 1 |
Corti, R | 1 |
Pazzi, P | 1 |
Scagliarini, R | 1 |
Gamberini, S | 1 |
Matarese, V | 1 |
Rizzo, C | 1 |
Gullini, S | 1 |
Bethke, TD | 1 |
Meier, E | 1 |
Meining, A | 1 |
Dattilo, M | 1 |
Figura, N | 1 |
Cammarota, G | 2 |
Papa, A | 1 |
Cianci, R | 1 |
Cannizzaro, O | 1 |
Armuzzi, A | 3 |
Gasbarrini, A | 3 |
Addolorato, G | 1 |
Gasbarrini, GB | 1 |
Abdul Aal, GM | 1 |
Dajani, AI | 2 |
Nounou, M | 1 |
Awad, S | 2 |
Abdul Rasheed, Z | 2 |
Gautam, S | 2 |
Ukabam, S | 2 |
Nayal, S | 2 |
Nounou, MA | 1 |
Abdul Aal, G | 1 |
Cain, C | 1 |
Catalano, F | 2 |
Branciforte, G | 2 |
Catanzaro, R | 2 |
Bentivegna, C | 2 |
Cipolla, R | 2 |
Nuciforo, G | 2 |
Brogna, A | 2 |
Rodríguez Téllez, M | 1 |
Valenzuela Barranco, M | 1 |
Caballero Plasencia, A | 1 |
Martín Ruiz, J | 1 |
López-Andrade, A | 1 |
Carmona Soria, I | 1 |
Herrerías Gutiérrez, J | 1 |
Boeck, W | 1 |
Richter, C | 1 |
Marre, R | 1 |
Lamouliatte, H | 2 |
Samoyeau, R | 2 |
De Mascarel, A | 2 |
Megraud, F | 2 |
Dillon, J | 1 |
Axon, AT | 1 |
Cooper, BT | 1 |
Tildesley, G | 1 |
Wyatt, JI | 1 |
Braun, W | 1 |
Vcev, A | 2 |
Ivandić, A | 2 |
Vceva, A | 2 |
Takac, B | 2 |
Dammann, HG | 1 |
Fölsch, UR | 1 |
Hahn, EG | 1 |
von Kleist, DH | 1 |
Klör, HU | 1 |
Schweeger, I | 1 |
Fitscha, P | 1 |
Sinzinger, H | 1 |
Ojetti, V | 2 |
Pitocco, D | 1 |
Silveri, NG | 1 |
Pola, P | 2 |
Ghirlanda, G | 1 |
Gasbarrini, G | 2 |
Carpio, D | 1 |
Marcos, S | 1 |
Gisbert, JL | 1 |
García Grávalos, R | 1 |
Vukobrat-Bijedić, Z | 1 |
Lacević, N | 1 |
Bratović, I | 1 |
Gribajcević, M | 1 |
Gogov, B | 1 |
Radović, S | 1 |
Battaglia, G | 1 |
Germanà, B | 1 |
Marin, R | 1 |
Valerio, G | 2 |
Frevel, M | 1 |
Daake, H | 1 |
Janisch, HD | 1 |
Kellner, HU | 1 |
Krezdorn, HG | 1 |
Tanneberger, D | 1 |
Wack, R | 1 |
Howden, CW | 1 |
Goh, K | 1 |
Parasakthi, N | 1 |
Cheah, P | 1 |
Ranjeev, C | 1 |
Rosmawati, M | 1 |
Tan, Y | 1 |
Chin, S | 1 |
Giannini, E | 1 |
Romagnoli, P | 1 |
Fasoli, A | 1 |
Chiarbonello, B | 1 |
Malfatti, F | 1 |
Botta, F | 1 |
Risso, D | 1 |
Lantieri, PB | 1 |
Testa, R | 1 |
Jungnickel, PW | 1 |
Calabrese, C | 1 |
Di Febo, G | 1 |
Areni, A | 1 |
Scialpi, C | 1 |
Biasco, G | 1 |
Miglioli, M | 1 |
Tincani, E | 1 |
Bertoni, G | 1 |
Silingardi, M | 1 |
Ghirarduzzi, A | 1 |
Bedogni, G | 1 |
Iori, I | 1 |
Rosandić, M | 1 |
Cremonini, F | 1 |
Bartolozzi, F | 1 |
Canducci, F | 1 |
Candelli, M | 1 |
Santarelli, L | 1 |
De Lorenzo, A | 1 |
Clemente, R | 1 |
Villani, MR | 3 |
Quitadamo, M | 3 |
Caruso, N | 1 |
Bergoli, ML | 1 |
Broutet, N | 1 |
Marais, A | 1 |
Salamon, R | 1 |
Meier, R | 1 |
Wettstein, A | 1 |
Drewe, J | 1 |
Geiser, HR | 1 |
Bardou, M | 1 |
Romanska, H | 1 |
Fischer, R | 2 |
Ng, W | 1 |
Lühmann, R | 1 |
Annese, V | 1 |
Niro, GA | 1 |
Bozzola, L | 1 |
Rassu, M | 1 |
Soffiati, G | 1 |
Behrendt, J | 1 |
Wenzel, C | 1 |
Herszényi, L | 1 |
Tulassay, Z | 1 |
Mayr-Kanhäuser, S | 1 |
Kränke, B | 1 |
Kaddu, S | 1 |
Müllegger, RR | 1 |
Kurbel, S | 1 |
Ostojić, R | 1 |
Barbir, A | 1 |
Hovat, D | 1 |
Mihaljević, S | 1 |
Barth, J | 1 |
Hahne, W | 1 |
Parente, F | 1 |
Sainaghi, M | 1 |
Sangaletti, O | 1 |
Imbesi, V | 1 |
Maconi, G | 1 |
Anderloni, A | 1 |
Bianchi Porro, G | 1 |
Vallve, M | 1 |
Gościmski, A | 1 |
Matras, J | 1 |
Wallner, G | 1 |
Meneghelli, UG | 1 |
Boaventura, S | 1 |
Moraes-Filho, JP | 1 |
Leitão, O | 1 |
Ferrari, AP | 1 |
Almeida, JR | 1 |
Magalhães, AF | 1 |
Castro, LP | 1 |
Haddad, MT | 1 |
Tolentino, M | 1 |
Jorge, JL | 1 |
Silva, E | 1 |
Maguilnik, I | 1 |
McColl, KE | 1 |
Nujumi, AM | 1 |
Dorrian, CA | 1 |
Macdonald, AM | 1 |
Fullarton, GM | 1 |
Harwood, J | 1 |
Clinical Trials (16)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes[NCT05449028] | 230 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan[NCT01769365] | Phase 4 | 307 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
"Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.[NCT00841854] | Phase 4 | 199 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT05049902] | Phase 4 | 1,300 participants (Actual) | Interventional | 2021-09-21 | Completed | ||
The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled Study[NCT05586113] | Phase 4 | 398 participants (Anticipated) | Interventional | 2023-02-06 | Not yet recruiting | ||
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT04901117] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2021-06-30 | Not yet recruiting | ||
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study[NCT00709046] | 150 participants (Anticipated) | Interventional | 2008-01-31 | Recruiting | |||
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239] | Phase 3 | 14 participants (Anticipated) | Interventional | 2015-02-28 | Not yet recruiting | ||
Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284] | Phase 3 | 300 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants in Which H. Pylori Was Eradicated
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
Intervention | participants (Number) |
---|---|
Pantoprazole+Bismuth+Tetra+Metro | 154 |
Hybrid Therapy | 154 |
Number of Participants in Which H. Pylori Was Eradicated
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
Intervention | participants (Number) |
---|---|
Pantoprazole+Bismuth+Tetra+Metro | 169 |
(Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Number of Participants With Complete Eradication of Helicobacter Pylori
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT01769365)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
Intervention | participants (Number) |
---|---|
7-day Quadruple Therapy | 102 |
10-day Sequential Therapy | 100 |
7-day Standard Triple Therapy | 101 |
Number of Participants With Healed Peptic Ulcer
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
Intervention | participants (Number) |
---|---|
Histamine-2 Receptor Antagonist Group | 106 |
Placebo Group | 101 |
Number of Participants With Ulcer Recurrence
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
Intervention | participants (Number) |
---|---|
Proton Pump Inhibitor Group | 1 |
Histamine-2 Receptor Antagonist Group | 7 |
Number of Participants in Which H. Pylori Was Eradicated
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
Intervention | participants (Number) |
---|---|
Reverse Hybrid Therapy | 206 |
Standard Triple Therapy | 191 |
Reviews
21 reviews available for pantoprazole and Helicobacter Infections
Article | Year |
---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based
Topics: Cytochrome P-450 CYP2C19; Helicobacter Infections; Humans; Pantoprazole; Polymorphism, Genetic; Prot | 2020 |
Long-term complete remission of primary gastric plasmacytoma following endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Gastric Mucosa; Gastroscopy; H | 2017 |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter In | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2003 |
Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Benzimidazoles; Drug Therapy, Combin | 2004 |
Understanding NSAID-PPI-COX-2 interrelationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
[Eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2005 |
[Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Benzimidazoles; Drug Therapy, Combin | 2005 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimi | 1996 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
[Role of pantoprazole in the eradicating treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Trials
112 trials available for pantoprazole and Helicobacter Infections
Article | Year |
---|---|
Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therap | 2019 |
Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Disease | 2017 |
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2017 |
Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc | 2018 |
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent | 2013 |
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2014 |
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2014 |
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2014 |
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2014 |
Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
[Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2015 |
Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2015 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinic | 2015 |
Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2016 |
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2015 |
Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Clarithromycin; Drug Administration Sche | 2017 |
Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Amoxicillin; Anorexia; Anti-Bacteria | 2017 |
[Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; | 2008 |
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2009 |
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; An | 2009 |
Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; Capsules; Carbon Radioisotopes; Citric Acid; | 2009 |
Periodontal therapy improves gastric Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2009 |
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydr | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diabete | 2009 |
The effect of mastic gum on Helicobacter pylori: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicob | 2010 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2009 |
Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Biopsy; Clarithro | 2010 |
Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Female; | 2010 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infectiv | 2010 |
Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diab | 2010 |
Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2011 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bism | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 2011 |
Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: are G-protein β3 subunit genotype, Helicobacter pylori status, and environmental factors response modifiers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Alcohol Drinking; Anti-Inflammato | 2011 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarith | 2012 |
Effective administration method of intravenous proton pump inhibitor: a novel testing using a BRAVO catheterless pH monitoring system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Analysis of Variance; Female; Gastric Acidity Determi | 2011 |
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2011 |
Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; | 2012 |
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2012 |
The efficacy of PPI after endoscopic hemostasis in patients with bleeding peptic ulcer and role of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacte | 2012 |
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compou | 2012 |
Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2013 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2002 |
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations | 2003 |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Ag | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; B | 2004 |
Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents | 2006 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infect | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2006 |
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2006 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Body Constitution; Cross-Over Stu | 2007 |
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Adminis | 2007 |
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Adult; Aged; Curcumin; Drug Therapy, Combin | 2007 |
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2007 |
A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug | 2007 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarit | 2008 |
Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Cla | 1999 |
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid | 1999 |
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Double-Blind Method; Enzyme In | 1999 |
Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Pantoprazole suppresses Helicobacter pylori without affecting cure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Thera | 1999 |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2000 |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bism | 2000 |
One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Aging; Amoxicillin; Anti-Bacterial Agent | 2000 |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Azithromycin; Benzimidazoles; Drug Therapy, Co | 2000 |
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2001 |
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz | 2001 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2001 |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Aging; Amoxi | 2001 |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2001 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Car | 2002 |
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans; | 2002 |
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzi | 2002 |
Other Studies
66 other studies available for pantoprazole and Helicobacter Infections
Article | Year |
---|---|
Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Female; Helicobac | 2020 |
The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Clinic | 2020 |
[Trend in the Eradication Rates of
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 2017 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes | 2018 |
Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Cytochrome P-450 CYP2C19; | 2019 |
Case report: Helicobacter suis infection in a pig veterinarian.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Clarith | 2013 |
Might Helicobacter pylori infection be associated with distortion on taste perception?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Clarithromycin; Dysgeusia; Female; G | 2013 |
Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; C | 2013 |
Not All Helicobacter Are pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Biopsy; Clarithromycin; | 2015 |
Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2015 |
In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Ba | 2015 |
Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Diabetes M | 2015 |
Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Chi-Square Distribution; Chronic Diseas | 2015 |
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; D | 2016 |
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytoc | 2016 |
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Drug Therapy, Combination; Female; H | 2016 |
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; ATP Binding Cassette Transport | 2017 |
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 2017 |
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
[Eosinophilic gastritis after helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Burkitt Lymphoma; Female; Gastric | 2009 |
Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Prote | 2010 |
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
[Acute psychosis induced by a Helicobacter pylori (H. pylori)-eradication treatment with amoxicillin, clarithromycin and pantoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
Effect of Helicobacter pylori infection on symptoms of gastroenteritis due to enteropathogenic Escherichia coli in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Diarrhea; Enteropathogenic Escher | 2011 |
Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Sequential therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2010 |
[A case of Menetrier's disease showing mucus bridge observed during endoscopy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2011 |
Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Esophagogastric Junction; Female; G | 2011 |
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2012 |
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2012 |
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2012 |
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2012 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esophagitis, Peptic; Female; Gastric Mucosa; Helicob | 2012 |
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2002 |
[Patient with increased stomach cancer risk. Helicobacter can cause damage here].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2002 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Develop | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2004 |
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count; | 2005 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Helicobacter pylori: factors affecting eradication and recurrence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
Eradication of Helicobacter pylori and dosages of esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2006 |
Thyroxine in goiter, H. pylori infection, and gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adsorption; Anti-Ulcer Agents; Benzimidazoles; Biological A | 2006 |
Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2007 |
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Ag | 2007 |
[Reliable Helicobacter eradication. Combination package facilitates therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Packag | 2006 |
Efficacy of clarithromycin-based triple therapy for treating Helicobacter pylori in Thai non-ulcer dyspeptic patients with clarithromycin-resistant strains.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2006 |
The eradication of Helicobacter pylori is affected by body mass index (BMI).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Body | 2008 |
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He | 1998 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
Treatment of antibiotic-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 1998 |
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
[Is dental plaque a normal Helicobacter pylori reservoir?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari | 1998 |
Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; | 1998 |
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute-Phase Reaction; Adult; Aged; Anti-Bacterial Agents; A | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Amoxicillin; Anti-Ulcer Agents; | 2000 |
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles | 2001 |
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Benzimidazoles; Duodenal Ulcer; | 1992 |